Overall, these results imply that targeting the FOXO3/FOXM1 axis is a conceptually sound therapeutic strategy for the treatment of BC due to the transcriptional regulation of genes involved in cell cycle control and DDR by the FOXO3/FOXM1 axis, as well as the possibility that it is linked to mitotic catastrophe. This evidence concerns the gene FOXM1 and breast cancer.